SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the ...
Cellular Origins and Fresenius Kabi, an operating company ... treatment while reducing development and manufacturing costs. The U.S. Food and Drug Administration (FDA) has approved flurpiridaz ...
B. Braun and Fresenius Medical Care said they will make more crucial products as the U.S. faces shortages following Hurricane Helene’s damage to a Baxter manufacturing facility.